SL-176 displays an inhibitory profile which deviates from the one seen in the allosteric WIP1 inhibitor GSK2830371: while the latter exhibits its inhibitory effect only in sensitive cell lines with wild-type TP53 [61,75], SL-176 affects the viability of virtually all tested NB and MB cell lines with IC50 values around 1 μM, regardless of TP53 mutational status, while non-cancerous cell lines show much lower sensitivity (Figure 4A and Figure S2B) [76]. This evidence concerns the gene TP53 and neuroblastoma.